Find Clinical Trials

Brain

November 29, 2022 in Brain

BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NCT05438212)

Read More
September 14, 2022 in Brain

A071401

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS
Read More
June 30, 2022 in Brain

EAF151

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Read More
June 30, 2022 in Brain

CE.7

A phase III trial of stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases.
Read More
June 30, 2022 in Brain

BN011

BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma (NCT 05095376)
Read More
June 30, 2022 in Brain

BN007

BN007: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (NCT 04396860)
Read More
See All

Breast

October 26, 2022 in Breast

evERA ML43171

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR…
Read More
August 16, 2022 in Breast

S2007

S2007: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases (NCT 04647916)
Read More
July 11, 2022 in Breast

S1706

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
Read More
July 11, 2022 in Breast

S1703

S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Read More
July 1, 2022 in Breast

MA-39

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
Read More
June 30, 2022 in Breast

EAQ201

EAQ201: COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation (NCT 05076266)
Read More
See All

Cancer Control / CCDR

November 30, 2022 in Cancer Control / CCDR

S2108CD: A CLUSTER RANDOMIZED TRIAL COMPARING AN EDUCATIONALLY ENHANCED GENOMIC TUMOR BOARD (EGTB) INTERVENTION TO USUAL PRACTICE TO INCREASE EVIDENCE-BASED GENOME-INFORMED THERAPY

Read More
November 22, 2022 in Cancer Control / CCDR

U21038: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Read More
September 14, 2022 in Cancer Control / CCDR

A231602CD

Improving surgical care and outcomes in Older cancer Patients Through Implementation of an efficient pre-Surgical toolkit (OPTI-Surg)
Read More
August 10, 2022 in Cancer Control / CCDR

A222004

A222004: A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia (NCT04939090)
Read More
July 11, 2022 in Cancer Control / CCDR

WF1805CD

WF1805CD: Implementation and Effectiveness Trial of HN-STAR
Read More
July 11, 2022 in Cancer Control / CCDR

WF1801

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Read More
See All

Gastrointestinal

October 20, 2022 in Gastrointestinal (GI)

Actuate 1801

Study Protocol 1801, Part 3 Arm B: Randomized Phase 2 Study of Gemcitabine/Nab-Paclitaxel Plus 9-ING-41 in Patients with Previously Untreated Metastatic Pancreatic Cancer
Read More
October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…
Read More
October 11, 2022 in Gastrointestinal (GI)

S2107

Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer (NCT #05308446)
Read More
September 14, 2022 in Gastrointestinal (GI)

GI003

GI003: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Read More
August 31, 2022 in Gastrointestinal (GI)

C-14 (CORRECT-MRD II)

CORRECT-MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Read More
July 11, 2022 in Gastrointestinal (GI)

WF1806

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M and M Study (NCT03998202)
Read More
See All

Genitourinary

October 14, 2022 in Genitourinary (GU)

CAPItello-280

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer…
Read More
October 11, 2022 in Genitourinary (GU)

GU012

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (NCT# 05327686)
Read More
September 21, 2022 in Genitourinary (GU)

A032101

A phase 2 trial of ADT interruption in patients responding exceptionally to AR pathway inhibitor in metastatic hormone-sensitive prostate cancer (MHSPC): A-DREAM NCT #05241860
Read More
August 26, 2022 in Genitourinary (GU)

EA8191

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (NCT04423211)
Read More
July 11, 2022 in Genitourinary (GU)

WF1802

​WF1802: Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW) ​
Read More
July 11, 2022 in Genitourinary (GU), Melanoma

SGNLVA-005

SGNLVA-005: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Read More
See All

Gynecology

September 21, 2022 in Gynecology

GY026

A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma…
Read More
August 31, 2022 in Gynecology

FLORA-5/GOG 3035

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Read More
June 30, 2022 in Gynecology

GY023

GY023: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib…
Read More
June 30, 2022 in Gynecology

GY019

GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Read More
June 30, 2022 in Gynecology

GY014

GY014: A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Read More
June 30, 2022 in Gynecology

GY012

Olaparib, Cediranib Maleate, and Wee1 Inhibitor AZD1775 in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer
Read More
See All

Head and Neck

September 14, 2022 in Head and Neck

EA3202

EA3202: A Phase II/III trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Read More
July 1, 2022 in Head and Neck

HN009

HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell…
Read More
July 1, 2022 in Head and Neck

HN001

HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Read More
June 30, 2022 in Head and Neck

EA3191

EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Read More
June 30, 2022 in Head and Neck

EA3161

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Read More
June 30, 2022 in Head and Neck

EA3132

Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Read More
See All

Hematology

December 8, 2022 in Hematology

MOR208C310 (frontMIND)

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients…
Read More
November 9, 2022 in Hematology

EA9152: A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Read More
September 14, 2022 in Hematology

S1803

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct…
Read More
July 11, 2022 in Hematology

S1925

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small…
Read More
July 11, 2022 in Hematology

S1826

S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (12+ Years Old) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma…
Read More
July 11, 2022 in Hematology

S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Read More
See All

Lung

October 24, 2022 in Lung

S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib (LY3527723) In Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease…
Read More
September 15, 2022 in Lung

EMERGE-402

EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Read More
September 14, 2022 in Lung

LungMAP

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Read More
September 14, 2022 in Lung

EA5162

EA5162: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Read More
August 31, 2022 in Lung

DREAM3R/PrE0506

DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
Read More
August 31, 2022 in Lung

APL-101-01

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met…
Read More
See All

Melanoma

August 16, 2022 in Melanoma

A091903

A091903: A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma (NCT05111574)
Read More
July 11, 2022 in Genitourinary (GU), Melanoma

SGNLVA-005

SGNLVA-005: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Read More
July 11, 2022 in Melanoma

S2000

S2000: A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases
Read More
June 30, 2022 in Melanoma

EA6141

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Read More
June 30, 2022 in Melanoma

A091802

​A091802: Phase II randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma of the skin (cSCC​
Read More
See All

MNCCTN

December 1, 2022 in MNCCTN

EH21C1 (MNCCTN027)

Topical cannabidiol (CBD) for the treatment of chemotherapy-induced peripheral neuropathy: a randomized placebo-controlled pilot trial
Read More
December 1, 2022 in MNCCTN

EH21C1 (MNCCTN024)

A Prospective, Randomized Study To Evaluate The Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12 Weeks
Read More
August 4, 2022 in MNCCTN

MC19C1 (MNCCTN009)

Rose Geranium in Sesame Oil Nasal Spray as an Agent to Improve Symptoms of Nasal Vestibulitis: A Phase III Double Blinded Randomized Controlled Trial
Read More
See All

Sarcoma

June 30, 2022 in Sarcoma

A091902

A091902: A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
Read More
See All

Other Sites

September 7, 2022 in Other Sites

TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
Read More
August 31, 2022 in Other Sites

SGNTUC-019

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Read More
August 31, 2022 in Other Sites

CRESTONE

A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Read More
July 11, 2022 in Other Sites

U19075

U19075: Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Read More
July 11, 2022 in Other Sites

S2012

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Read More
July 11, 2022 in Other Sites

S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Read More
See All